Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01997879 · ClinicalTrials.gov registry record · Phase 1
Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers
A Phase 1 study of Healthy, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01997879: Completed Phase 1 study of Healthy, sponsored by Aerie Pharmaceuticals.
NCT01997879 is a Phase 1 study of Healthy that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 18 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01997879, a Phase 1 study of Healthy, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess systemic safety and absorption of AR-13324 in healthy volunteers.
Primary Outcome
Blood samples obtained to evaluate the systemic exposure (Area Under the Curve (AUC), Maximum Concentration, Time and half-life (Cmax, tmax and t ½)) to ocularly instilled AR-13324 and its metabolites as appropriate.
Conditions Studied
Interventions
- DRUG AR-13324 Ophthalmic Solution, 0.02%
Study Locations (1)
Arizona
- Celerion - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
What the finished NCT01997879 record still lists
NCT01997879 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which AR-13324 Ophthalmic Solution, 0.02% is the first listed.
NCT01997879 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT01997879 about?
NCT01997879 is a clinical study titled "Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers". The purpose of this study is to assess systemic safety and absorption of AR-13324 in healthy volunteers.
What is the current status of trial NCT01997879?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-11. Estimated completion is 2013-11.
What conditions does trial NCT01997879 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT01997879?
The interventions under investigation include: AR-13324 Ophthalmic Solution, 0.02% (DRUG).
Who is sponsoring clinical trial NCT01997879?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01997879 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01997879's enrollment target sits among peer trials
18 904th of 1090 higher than 163 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia